Ruplu, Steve here. So to answer your question, first, let me go back to my comments this time last year, and then I'll give you the go-forward perspective. First, I mentioned last year at this time, the overall med device market is growing roughly 3% to 4%. And on that call, I said my expectation was we would return to growth in fiscal year '26, driven by our past wins in the areas that Mike mentioned in his opening remarks, GLP and biologics growing and getting into production. And that's continued as planned, most especially to answer your question on Croatia. Equation is on track as planned. There has been no changes. There are no delays. So that's moving forward as we anticipated. In addition, this year, your question about new wins, in addition, I'd say that we have quite a few new ones. They're in the areas of med devices, CGMs and general auto-injector growth. That's driven not just by GLP-1s though, but by biologics. I've mentioned in prior calls, the growth that we're seeing in the Pharma segment as it relates to biologics and the need for injectors to support that. And as a matter of fact, we recently added a new win for our Dominican Republic site that's going to leverage our new sterilization capability, which we recently invested in. But as we've talked about before, these ramps due to automation, lead times, regulatory validation requirements will take some time to ramp, but those are some really, really good new wins for us. And I'd say, in addition, we sit today with our largest funnel of B2Bs, which is obviously not forecasted, but could create some opportunities this fiscal year depending on timing. And then I'd say last but not least, in our video, we mentioned the Pii transaction, and it is on track, and we're excited that the team has already added a new customer, and we have many visits planned now that the integration is complete. So to summarize, a very long answer, sorry, is what I'm trying to say is that with the new wins even from last year and the ones this year that I expect growth rate in health care to be at or above the 5% range going forward.